XENE Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals to Present at Jefferies Inaugural Biotech CNS/Neuro Summit

Xenon Pharmaceuticals to Present at Jefferies Inaugural Biotech CNS/Neuro Summit

VANCOUVER, British Columbia, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at Jefferies Inaugural Biotech CNS/Neuro Summit to be held on October 11, 2023.

Company Fireside Chat Presentation Details:

Date:Wednesday, October 11, 2023
  
Time:2:25 PM Eastern Time
  
Webcast:
  
Presenters:Ian Mortimer, President and Chief Executive Officer

Sherry Aulin, Chief Financial Officer

  

A live webcast of the company presentation will be available on the “” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit .

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:

Jodi Regts

Xenon Pharmaceuticals Inc.

Phone: (604) 484-3353

Email:



EN
06/10/2023

Underlying

XENEXenon Pharmaceuticals Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Xenon Pharmaceuticals Inc

Wedbush Research
  • Wedbush Research
W WAYFAIR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
PANW PALO ALTO NETWORKS INC.
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
ETSY ETSY INC.
EBAY EBAY INC.
CRM SALESFORCE.COM INC.
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
AXTI AXT INC.
ACRS ACLARIS THERAPEUTICS INC.
2303 UNITED MICROELECTRONICS CORP.
ARGX ARGENX ADS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
CHWY CHEWY INC. CLASS A
SMCI SUPER MICRO COMPUTER
IDYA INC.
DASH IDEAYA BIOSCIENCES
PLTR DOORDASH
STX PALANTIR TECHNOLOGIES
TMC SEAGATE TECHNOLOGY HLDGS PLC
GFS THE METALS COMPANY INC
PL GLOBALFOUNDRIES INC
APGE PLANET LABS PBC
DNTH APOGEE THERAPEUTICS INC
CRBP DIANTHUS THERAPEUTICS INC
CART CORBUS PHARMACEUTICALS HOLDINGS INC.
RNAC MAPLEBEAR INC.
TLX CARTESIAN THERAPEUTICS INC
VOYG TELIX PHARMACEUTICALS LIMITED
VOYAGER TECHNOLOGIES INC
14h / 50m 14h / 50m 1 EN
Laura Chico ... (+2)
  • Laura Chico
  • Thomas Yip
XENE XENON PHARMACEUTICALS INC
16h / 14m 16h / 14m 1 EN
 PRESS RELEASE
Free
XENE Xenon Pharmaceu...

Xenon Pharmaceuticals Announces Proposed Public Offering

Xenon Pharmaceuticals Announces Proposed Public Offering VANCOUVER, British Columbia and BOSTON, MA, March 09, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that it has commenced an underwritten public offering of $500.0 million of its common shares, pursuant to its existing shelf registration statement. All of the common shares in this offering are being offered by Xenon. In addit...

March 9, 2026 1 EN
 PRESS RELEASE
Free
XENE Xenon Pharmaceu...

Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Az...

Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS) X-TOLE2 met primary endpoint in both dose groups, including -53.2% median percent change (MPC) from baseline in monthly FOS frequency with 25 mg dose compared with -10.4% for placebo (p=0.000000000006)X-TOLE2 outperformed Phase 2b X-TOLE study, with a placebo-adjusted MPC of -42.7% in 25 mg group in X-TOLE2 compared to -34.6% in 25 mg group in X-TOLEAzetukalner was generally well-tolerated with a safety profile consistent with X-TOLE studyXenon anticipates submitting New Drug Applic...

March 9, 2026 1 EN
Wedbush Research
  • Wedbush Research
LOGI LOGITECH INTERNATIONAL S.A.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
BIIB BIOGEN INC.
BBY BEST BUY CO. INC.
AXTI AXT INC.
ARDX ARDELYX INC
2303 UNITED MICROELECTRONICS CORP.
ARGX ARGENX ADS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
HEAR TURTLE BEACH CORP.
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
CRSR INC.
DAWN CORSAIR GAMING
STX DAY ONE BIOPHARMACEUTICALS INC
TTD SEAGATE TECHNOLOGY HLDGS PLC
GFS THE TRADE DESK
EWTX INC.
NATL GLOBALFOUNDRIES INC
CAMP EDGEWISE THERAPEUTICS INC
JBIO NCR ATLEOS CORPORATION
CAMP4 THERAPEUTICS CORPORATION
JADE BIOSCIENCES INC
03/09/26 March 9, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch